This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...

Medically reviewed by David Ozeri, MD C3G (Complement 3 Glomerulopathy) and IC-MPGN (Immune Complex Membranoproliferative ...

Pegcetacoplan has been approved for the treatment of C3 glomerulopathy or primary immune complex membranoproliferative ...

I’m excited to now have a highly effective therapy for a broad range of patients living with C3G and primary IC-MPGN,” said ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

The FDA has approved Empaveli for the treatment of adult and pediatric patients aged 12 years and older with C3G or primary ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts. On July 29, Apellis announced that the US FDA approved EMPAVELI (pegcetacoplan) as the ...

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

DelveInsight's“ IC-MPGN – Market Insights, Epidemiology, and Market Forecast – 2034 ” delivers a deep dive analysis of the evolving disease landscape, highlighting epidemiological patterns ...